HIV/AIDS Headlines

Tenofovir Use Safe During Pregnancy

Tenofovir Use Safe During Pregnancy

Further research on longer-term effects of maternal prenatal TDF use is important given the majority of HIV-infected women are prescribed a TDF-containing prevention of mother-to-child transmission regimen.

Dual Regimen Provides Simple and Safe Salvage Therapy in HIV-1

Dual Regimen Provides Simple and Safe Salvage Therapy in HIV-1

Switching to dolutegravir plus darunavir/ritonavir provided a simple and safe rescue regimen, controlling viral replication in a high proportion of patients.

Carotid Plaque, Risk of Vascular Disease Events Higher in HIV

Carotid Plaque, Risk of Vascular Disease Events Higher in HIV

Findings show that HIV status was associated with an increased rate of incidental carotid plaque, noncalcified plaque, and high-risk plaque.

Efficacy of Maraviroc-Containing HIV PrEP in Women Evaluated

Efficacy of Maraviroc-Containing HIV PrEP in Women Evaluated

Maraviroc (MVC)-containing HIV PrEP regimens are well tolerated for preventing HIV infection in uninfected women.

Adolescents at Risk for HIV Should Be Offered PrEP

Adolescents at Risk for HIV Should Be Offered PrEP

Experts discuss new findings supporting the need for PrEP in adolescents and discuss the continued debate surrounding parental consent and other relevant issues.

CDC Contraception Recommendations Updated for Women at Risk for HIV

CDC Contraception Recommendations Updated for Women at Risk for HIV

Women should not be denied the use of progestin-only injectables because of concerns about the possible increased risk of acquiring HIV.

Once-Daily Raltegravir Safe, Effective for Initial HIV Treatment

Once-Daily Raltegravir Safe, Effective for Initial HIV Treatment

Once-daily regimens have been shown to improve adherence to treatment with no adverse effect on outcomes in patients with HIV.

Improving Linkage to Care in HIV Testing for Women

Improving Linkage to Care in HIV Testing for Women

Many women who are newly diagnosed with HIV have already been diagnosed but are not getting HIV medical care.

Pre-Exposure Prophylaxis Program for MSM Cost-Effective in UK

Pre-Exposure Prophylaxis Program for MSM Cost-Effective in UK

HIV PrEP in the UK for men who have sex with men might be cost-effective.

FDA Approves Dose Modification for Children With HIV

FDA Approves Dose Modification for Children With HIV

The FDA has approved labeling changes for Genvoya to include new safety and efficacy data.

HIV Diagnosis Notification Rates Up Among Older Adults

HIV Diagnosis Notification Rates Up Among Older Adults

Notification rates of new HIV diagnoses in older adults increased in 16 European countries from 2004 to 2015.

Assessing the Risk Factors of Neurocognitive Decline in HIV+ Individuals

Assessing the Risk Factors of Neurocognitive Decline in HIV+ Individuals

The incidence of neurocognitive impairment is high in HIV-infected population, despite the introduction of combination antiretroviral therapy (CART).

New Antiretroviral Therapy Recommendations for Pregnant Women With HIV

New Antiretroviral Therapy Recommendations for Pregnant Women With HIV

The GRADE framework recommendations provide guidance for combination treatment regimens based on 2 systemic reviews, patient considerations, fetal outcomes, and practical issues.

Clinical Practice Guidelines Updated for Chronic Pain Management in HIV

Clinical Practice Guidelines Updated for Chronic Pain Management in HIV

The Infectious Diseases Society of America recommends that people living with HIV be screened for pain.

PrEP Adherence in Adolescent MSM Decreases Over Time

PrEP Adherence in Adolescent MSM Decreases Over Time

PrEP adherence decreases in adolescent MSM with quarterly visits during 48-week intervention.

SIGN UP FOR FREE E-NEWSLETTERS